An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse
Completed
- Conditions
- Glioblastoma Multiforme
- Registration Number
- NCT01618747
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse. Data will be collected from eligible patients initiated on Avastin treatment according to local label for up to 3 years.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Adults patients, >/= 18 years of age
- Histologically confirmed glioblastoma multiforme in first or second relapse
Exclusion Criteria
- Patients not qualifying for Avastin treatment as per local label
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival at 6 months approximately 3 years
- Secondary Outcome Measures
Name Time Method Progression-free survival approximately 3 years Time to disease progression approximately 3 years Duration of objective response approximately 3 years Overall survival approximately 3 years Safety: Incidence of adverse events approximately 3 years